Area of research
Orthopedics and Sports Medicine · Oncology
Research interest
Research interests include Bone health and osteoporosis research, Bone health and treatments, Bone Metabolism and Diseases, and Bone and Joint Diseases.
A consensus statement on the management of vertebral fractures in CKD stages G4–G5D
Goal-directed osteoporosis treatment: ASBMR/BHOF task force position statement 2024
The relationship between treatment-related changes in total hip BMD measured after 12, 18, and 24 mo and fracture risk reduction in osteoporosis clinical trials: the FNIH-ASBMR-SABRE project
The relationship between baseline bone mineral density and fracture incidence in the placebo groups of randomized controlled trials using individual patient data from the FNIH-ASBMR-SABRE project
Influence of age on the efficacy of pharmacologic treatments on fracture risk reduction and increases in BMD: RCT results from the FNIH-ASBMR-SABRE project
Biochemical Markers of Bone Fragility in Patients With Diabetes
Bone fragility in diabetes: novel concepts and clinical implications
Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension
Bisphosphonates and the risk of atypical femur fractures
Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update
Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates
Fracture Risk and Management of Discontinuation of Denosumab Therapy: A Systematic Review and Position Statement by ECTS
The risk of hip and non-vertebral fractures in type 1 and type 2 diabetes: A systematic review and meta-analysis update
Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials
Risks of Hip and Nonvertebral Fractures in Patients With CKD G3a-G5D: A Systematic Review and Meta-analysis
Denosumab in postmenopausal women with osteoporosis and diabetes: Subgroup analysis of FREEDOM and FREEDOM extension
Validation of the Surrogate Threshold Effect for Change in Bone Mineral Density as a Surrogate Endpoint for Fracture Outcomes: The FNIH-ASBMR SABRE Project
Diabetes Mellitus and the Benefit of Antiresorptive Therapy on Fracture Risk
Bone Turnover Markers Do Not Predict Fracture Risk in Type 2 Diabetes
Real-world bone turnover marker use: impact on treatment decisions and fracture
Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline
Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials
Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline
Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period
The Efficacy and Safety of Vertebral Augmentation: A Second ASBMR Task Force Report
Association Between Drug Treatments for Patients With Osteoporosis and Overall Mortality Rates
The risk of hip and non-vertebral fractures in patients with Parkinson's disease and parkinsonism: A systematic review and meta-analysis
Diagnosis and management of bone fragility in diabetes: an emerging challenge
Determination of Free 25(OH)D Concentrations and Their Relationships to Total 25(OH)D in Multiple Clinical Populations
Treatment-Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Anti-Resorptive Drugs: A Meta-Regression